Information Provided By: 
Fly News Breaks for April 27, 2016
DVAX
Apr 27, 2016 | 10:46 EDT
Cowen analyst Phil Nadeau does not beleive Dynavax's Heplisav PDUFA extension by 3 months will impact chances of approval. The analyst suspects that the PDUFA change has more to do with FDA managing its workload than any reflection on the substance of the BLA, since both the FDA and Dynavax had agreed upon the original format of the BLA resubmission. Nadeau continues to rate Dynavax an Outperform and top small cap pick with a $60 price target on shares.
News For DVAX From the Last 2 Days
There are no results for your query DVAX
